MROH5 and neutropenia: PTP4A3 represents a strong causal candidate for neutropenia as treatment of mice with a PTP4A3 derived peptide reduced endotoxemia-induced septic shock.27PTP4A3 expression has also been associated with poor prognosis in CRC possibly due to a role in metastasis and tumour invasion,28,29 and has been implicated in resistance to chemotherapy.30,31 Importantly, the strength of the relationship between SNPs in MROH5 and neutropenia suggests that they may have clinical utility as predictive biomarkers.